Sibylla Biotech

CompanyItalyFounded 2017

Sibylla Biotech develops one asset, preclinical (Cyclin D1 degrader in hr+ breast cancer). Mostly small molecule acting on CCND1; based in Italy, founded in 2017.

1
Asset
Furthest stage: Preclinical
Raised: €23m; 0
Trials: 0
Signals

Pipeline

1

Cyclin D1 degrader
Interferes with Cyclin D1 protein folding to induce its degradation.
Preclinical, Small molecule, CCND1, hr+ breast cancer

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms1
Funding rounds and grants1
People13